← Sarepta Therapeutics, Inc.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $5.4m |
$154.6m
+2751.58%
|
$301.0m
+94.74%
|
$380.8m
+26.51%
|
$455.9m
+19.70%
|
$612.4m
+34.34%
|
$843.8m
+37.78%
|
$1.2b
+47.36%
|
$1.9b
+52.97%
|
$2.2b
+15.58%
|
$2.0b
-10.19%
|
|
| Cost of Goods and Services Sold | $130k |
$203.5m
+156469.23%
|
$436.9m
+114.65%
|
$801.6m
+83.47%
|
$702.2m
-12.40%
|
$789.5m
+12.43%
|
$928.5m
+17.62%
|
$1.0b
+10.85%
|
$1.1b
+9.40%
|
$25.5m
-97.74%
|
$807.6m
+3067.20%
|
|
| Gross Profit (Calculated) (derived) | $5.3m |
($49.0m)
-1025.27%
|
($135.9m)
-177.53%
|
($420.8m)
-209.68%
|
($246.3m)
+41.46%
|
($177.1m)
+28.11%
|
($84.8m)
+52.12%
|
$214.0m
+352.47%
|
$776.0m
+262.52%
|
$1.8b
+136.97%
|
— | |
| Research and Development Expense | $188.3m | $166.7m | $401.8m | — | — | — | — | — | — | — | $789.4m | |
| Selling, General and Administrative Expense | $83.7m | $122.7m | $207.8m | $284.8m | $317.9m | $282.7m | $451.4m | $481.9m | $557.9m | $491.7m | $436.7m | |
| Amortization of Intangible Assets | — | $1.1m | $865k | $849k | $662k | $706k | $714k | $1.6m | $2.4m | $2.6m | — | |
| Restructuring Costs | $4.6m | $3.0m | ($2.2m) | — | — | — | — | — | — | $134k | — | |
| Operating expenses: | ||||||||||||
| Operating Income (Loss) | ($266.7m) |
($171.6m)
+35.65%
|
($343.6m)
-100.21%
|
($705.6m)
-105.33%
|
($564.2m)
+20.04%
|
($459.7m)
+18.51%
|
($536.2m)
-16.64%
|
($267.8m)
+50.05%
|
$218.1m
+181.43%
|
($699.8m)
-420.88%
|
($62.2m)
+91.11%
|
|
| Interest Expense | — | $5.8m | $33.7m | $30.7m | $59.9m | $63.5m | $53.2m | $22.0m | ($18.4m) | ($38.1m) | $71.6m | |
| Interest Expense, Debt | — | — | — | — | — | — | $53.2m | $22.0m | $20.6m | $34.8m | $71.6m | |
| Gain (Loss) on Investments | — | — | — | — | — | — | — | — | — | ($15.9m) | — | |
| Other Nonoperating Income (Expense) | ($535k) | ($2.0m) | ($656k) | ($236k) | $517k | ($936k) | — | $33.1m | $42.7m | ($19.3m) | — | |
| Income (Loss) from Equity Method Investments | — | — | — | — | — | — | — | — | $0 | $0 | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | $45.7m | ($309.3m) | ($489.7m) | ($205.0m) | ($47.6m) | ($251.4m) | ($238.7m) | $168.7m | ($635.7m) | ($130.9m) | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | — | ($48.6m) | ($362.6m) | ($713.9m) | ($553.1m) | ($418.9m) | ($690.0m) | ($520.1m) | $260.8m | ($702.2m) | ($130.9m) | |
| Current Income Tax Expense (Benefit) | — | $48.6m | ($452k) | $1.6m | $1.3m | $141k | $14.1m | $16.0m | $25.8m | $11.5m | $5.8m | |
| Income Tax Expense (Benefit) | — | $2.1m | ($692k) | $1.2m | $1.1m | ($168k) | $13.5m | $15.9m | $25.5m | $11.2m | $5.8m | |
| Net Income (Loss) Attributable to Parent | ($267.3m) |
($50.7m)
+81.03%
|
($361.9m)
-614.01%
|
($715.1m)
-97.58%
|
($554.1m)
+22.51%
|
($418.8m)
+24.43%
|
($703.5m)
-67.99%
|
($536.0m)
+23.81%
|
$235.2m
+143.89%
|
($713.4m)
-403.27%
|
($136.7m)
+80.84%
|
|
| Earnings Per Share, Basic | — | — | — | — | — | ($5.15) | ($8.03) | ($5.80) | $2.47 | ($7.13) | ($1.46) | |
| Earnings Per Share, Diluted | — | — | — | — | — | — | ($8.03) | ($5.80) | $2.34 | ($7.13) | ($1.57) | |
| Weighted Average Number of Shares Outstanding, Basic | 48.7m | 58.8m | 66.2m | 73.6m | 78.0m | 81.3m | 87.6m | 92.4m | 95.1m | 100.1m | 103.9m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | 73.6m | 78.0m | 81.3m | 87.6m | 92.4m | 107.9m | 100.1m | 112.4m | |
| Additional Financial Items | ||||||||||||
| Costs and Expenses | $272.2m | $326.2m | $644.7m | $1.1b | $1.1b | $1.2b | $1.5b | $1.5b | $1.7b | $2.9b | — |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.